Gilead Sciences, Inc. $GILD Shares Bought by Groupe la Francaise

Groupe la Francaise boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 30.9% in the 2nd quarter, HoldingsChannel reports. The firm owned 49,627 shares of the biopharmaceutical company’s stock after purchasing an additional 11,712 shares during the period. Groupe la Francaise’s holdings in Gilead Sciences were worth $6,270,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Paulson Wealth Management Inc. lifted its stake in Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after acquiring an additional 67 shares during the last quarter. Essex Financial Services Inc. lifted its position in shares of Gilead Sciences by 0.9% in the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after buying an additional 71 shares during the last quarter. Davidson Trust Co. lifted its position in shares of Gilead Sciences by 4.1% in the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock worth $262,000 after buying an additional 74 shares during the last quarter. Venture Visionary Partners LLC boosted its stake in shares of Gilead Sciences by 1.2% during the 4th quarter. Venture Visionary Partners LLC now owns 6,422 shares of the biopharmaceutical company’s stock worth $788,000 after acquiring an additional 76 shares in the last quarter. Finally, Financial Connections Group Inc. boosted its stake in shares of Gilead Sciences by 30.2% during the 1st quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 76 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of recent analyst reports. Zacks Research raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 31st. Leerink Partners cut Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Royal Bank Of Canada increased their price target on Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a report on Wednesday, August 5th. Truist Financial dropped their price target on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Finally, Barclays reduced their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $158.04.

Insider Activity at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the sale, the director directly owned 10,066 shares of the company’s stock, valued at $1,459,771.32. This trade represents a 33.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00. Following the transaction, the chief executive officer owned 592,133 shares in the company, valued at $77,160,851.23. This represents a 2.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 105,000 shares of company stock worth $14,495,820. Insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

GILD opened at $150.99 on Tuesday. Gilead Sciences, Inc. has a 1-year low of $108.46 and a 1-year high of $157.29. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The stock has a market capitalization of $187.22 billion, a price-to-earnings ratio of -56.55 and a beta of 0.33. The business has a 50 day moving average of $137.17 and a 200-day moving average of $136.36.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter last year, the company posted $2.01 earnings per share. Gilead Sciences’s quarterly revenue was up 10.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.48 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.